Regeneron Pharmaceuticals (REGN) Other Operating Expenses (2009 - 2026)

Regeneron Pharmaceuticals' Other Operating Expenses history runs 18 years deep, the most recent figure standing at $771.3 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $771.3 million in Q1 2026; TTM through Mar 2026 was $781.3 million, a 2150.66% increase from a year earlier, with the FY2025 full-year figure at $10.0 million, up 118.73% from the prior year.
• Other Operating Expenses improved to $771.3 million in Q1 2026 per REGN's latest filing, from $10.0 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $771.3 million in Q1 2026 and bottomed at -$15.5 million in Q4 2024.
• The 5-year median for Other Operating Expenses is $550000.0 (2023), against an average of $58.6 million.
• Across the five-year window, Other Operating Expenses tumbled 3200.0% in 2024 and soared 225.0% in 2025, its largest moves.
• Year by year, Other Operating Expenses stood at $6.6 million in 2022, then plunged by 92.42% to $500000.0 in 2023, then tumbled by 3200.0% to -$15.5 million in 2024, then soared by 164.52% to $10.0 million in 2025, then jumped by 7613.0% to $771.3 million in 2026.
• Per Business Quant, the three latest REGN Other Operating Expenses figures stand at $771.3 million (Q1 2026), $10.0 million (Q3 2025), and -$15.5 million (Q4 2024).